Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections. 

Biotechnology

Spero Therapeutics

Sath Shukla

Kristyn McCandless

Esther Rajavelu

Ed Sopp

Michael Pucci

Troy Lister

Timothy Keutzer

Thomas Parr

Susan Redican

Shekman Wong

Kathy Burke

Laura McGinn

Nivedita Bhatt

Ilia Terova

Hanna Kwak

Akash Jain

Jamie Brady

Myriah Satterfield

Indu Lakhani

Kamal Hamed

Frank E. Thomas

Tregoning Prior

Scott Jackson

John C. Pottage

David Musselman

Terese Hoekstra

Jay Blackington

Cristina Larkin

The Business Development & Market Access team at Spero Therapeutics is responsible for identifying and forging strategic partnerships, optimizing market entry strategies, and ensuring the accessibility of Spero's antibacterial and rare disease product candidates. This includes alliance management, sales execution, and establishing pathways for broad market adoption to tackle multi-drug resistant bacterial infections effectively.

Business Development & Market Access

Leadership Team

Directors Team

Clinical and Research Operations

Business Development & Market Access

About

Team members

Other teams at Spero Therapeutics

Leadership Team

Directors Team

Clinical and Research Operations